Welcome to the
Hepatitis B Foundation
Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520
March 3 – Arrowhead Research Corporation announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus infection. Read more.
Adult Immunization Retake: Lost Opportunities for Protection, Shared Responsibility
March 3 – According to Medscape, only 65% of healthcare professionals have been vaccinated to protect against hepatitis B in the U.S. Read more.
WHO Official Urges Hepatitis B Education in China
March 3 – While praising China’s efforts in reducing hepatitis B, Dr. Shin Young-soo, the World Health Organization (WHO) Western Pacific regional director, stressed more effort is needed to fight discrimination against hepatitis B virus carriers in China. Read more.
Small man, Great Power
March 3 – A chronic hepatitis B carrier in China shows the impact one, small man can have by empowering others with his sense of justice, and his courage to disclose his chronic HBV infection, and publicly raise awareness. Read more.
Hepatitis B Foundation and Hep B United Applaud USPSTF for Draft HBV Screening Recommendations
Feb. 10 - The United States Preventive Services Task Force (USPSTF) issued a draft “B” grade for HBV screening of populations most vulnerable to HBV infection, which includes foreign-born individuals from countries with a 2% or higher HBV prevalence rate. A "B" grade recommendation ensures that healthcare providers will increase HBV screening in high-risk populations and that insurance carriers will reimburse for the testing! Read more.
Dr. Robert Gish Becomes Medical Director for Hepatitis B Foundation
Feb 10 - An internationally renowned medical researcher in the field of viral hepatitis, Dr. Gish has made invaluable contributions to the understanding and treatment of hepatitis B, which is the world’s leading cause of liver cancer. A longtime supporter of the foundation’s mission and a member of the Scientific Advisory Board, Dr. Gish’s new role will further strengthen its research and advocacy efforts worldwide. Read more.
Page last modified March 3, 2014